Hepatitis B and C viruses and risk of non-Hodgkin lymphoma: A case-control study in Italy

Martina Taborelli, Jerry Polesel, Maurizio Montella, Massimo Libra, Rosamaria Tedeschi, Monica Battiston, Michele Spina, Francesco Di Raimondo, Antonio Pinto, Anna Crispo, Maria Grimaldi, Silvia Franceschi, Luigino Dal Maso, Diego Serraino

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: Hepatitis C virus (HCV) has been consistently associated to non-Hodgkin lymphoma (NHL); conversely, few studies have evaluated a comprehensive serological panel of hepatitis B virus (HBV) in NHL etiology. Methods: We conducted a case-control study in Italy in 1999-2014, enrolling 571 incident, histologically confirmed NHLs and 1004 cancer-free matched controls. Study subjects provided serum for HCV and HBV testing and for HCV RNA. Odds ratios (ORs) and corresponding 95 % confidence intervals (CIs) were estimated by logistic regression, adjusting for potential confounders. Results: Circulating HCV RNA was detected in 63 (11.1 %) NHL cases and 35 (3.5 %) controls (OR = 3.51, 95 % CI: 2.25-5.47). Chronic HBV infection (i.e., positive to HBV surface antigen - HBsAg+) was found in 3.7 % of cases and 1.7 % of controls (OR = 1.95, 95 % CI: 1.00-3.81); a significantly elevated OR was observed for B-cell NHL (2.11, 95 % CI: 1.07-4.15). People with serological evidence of past HCV or HBV infection, vaccination against HBV, or detectable antibodies against HBV core antigen (anti-HBc+) alone were not at increased NHL risk. Conclusions: Our results support a role of chronic HCV infection in NHL in Italy and suggest an involvement of HBV infection. Associations were clearest for B-cell NHL and diffuse large B-cell lymphoma. Prevention and treatment of HCV and HBV infection may diminish NHL incidence, notably in areas with high prevalence of hepatitis viruses infection.

Original languageEnglish
Article number27
JournalInfectious Agents and Cancer
Volume11
Issue number1
DOIs
Publication statusPublished - Jun 23 2016

Fingerprint

Hepatitis B virus
Hepacivirus
Non-Hodgkin's Lymphoma
Italy
Case-Control Studies
Virus Diseases
Odds Ratio
Confidence Intervals
B-Cell Lymphoma
Hepatitis B Surface Antigens
RNA
Hepatitis B Core Antigens
Hepatitis Viruses
Lymphoma, Large B-Cell, Diffuse
Chronic Hepatitis B
Chronic Hepatitis C
Vaccination
Logistic Models
Antibodies
Incidence

Keywords

  • Case-control study
  • Hepatitis B virus
  • Hepatitis C virus
  • Non-Hodgkin lymphoma

ASJC Scopus subject areas

  • Infectious Diseases
  • Oncology
  • Epidemiology
  • Cancer Research

Cite this

Hepatitis B and C viruses and risk of non-Hodgkin lymphoma : A case-control study in Italy. / Taborelli, Martina; Polesel, Jerry; Montella, Maurizio; Libra, Massimo; Tedeschi, Rosamaria; Battiston, Monica; Spina, Michele; Di Raimondo, Francesco; Pinto, Antonio; Crispo, Anna; Grimaldi, Maria; Franceschi, Silvia; Dal Maso, Luigino; Serraino, Diego.

In: Infectious Agents and Cancer, Vol. 11, No. 1, 27, 23.06.2016.

Research output: Contribution to journalArticle

@article{34943633a8b44907aa71da8e66e937a0,
title = "Hepatitis B and C viruses and risk of non-Hodgkin lymphoma: A case-control study in Italy",
abstract = "Background: Hepatitis C virus (HCV) has been consistently associated to non-Hodgkin lymphoma (NHL); conversely, few studies have evaluated a comprehensive serological panel of hepatitis B virus (HBV) in NHL etiology. Methods: We conducted a case-control study in Italy in 1999-2014, enrolling 571 incident, histologically confirmed NHLs and 1004 cancer-free matched controls. Study subjects provided serum for HCV and HBV testing and for HCV RNA. Odds ratios (ORs) and corresponding 95 {\%} confidence intervals (CIs) were estimated by logistic regression, adjusting for potential confounders. Results: Circulating HCV RNA was detected in 63 (11.1 {\%}) NHL cases and 35 (3.5 {\%}) controls (OR = 3.51, 95 {\%} CI: 2.25-5.47). Chronic HBV infection (i.e., positive to HBV surface antigen - HBsAg+) was found in 3.7 {\%} of cases and 1.7 {\%} of controls (OR = 1.95, 95 {\%} CI: 1.00-3.81); a significantly elevated OR was observed for B-cell NHL (2.11, 95 {\%} CI: 1.07-4.15). People with serological evidence of past HCV or HBV infection, vaccination against HBV, or detectable antibodies against HBV core antigen (anti-HBc+) alone were not at increased NHL risk. Conclusions: Our results support a role of chronic HCV infection in NHL in Italy and suggest an involvement of HBV infection. Associations were clearest for B-cell NHL and diffuse large B-cell lymphoma. Prevention and treatment of HCV and HBV infection may diminish NHL incidence, notably in areas with high prevalence of hepatitis viruses infection.",
keywords = "Case-control study, Hepatitis B virus, Hepatitis C virus, Non-Hodgkin lymphoma",
author = "Martina Taborelli and Jerry Polesel and Maurizio Montella and Massimo Libra and Rosamaria Tedeschi and Monica Battiston and Michele Spina and {Di Raimondo}, Francesco and Antonio Pinto and Anna Crispo and Maria Grimaldi and Silvia Franceschi and {Dal Maso}, Luigino and Diego Serraino",
year = "2016",
month = "6",
day = "23",
doi = "10.1186/s13027-016-0073-x",
language = "English",
volume = "11",
journal = "Infectious Agents and Cancer",
issn = "1750-9378",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Hepatitis B and C viruses and risk of non-Hodgkin lymphoma

T2 - A case-control study in Italy

AU - Taborelli, Martina

AU - Polesel, Jerry

AU - Montella, Maurizio

AU - Libra, Massimo

AU - Tedeschi, Rosamaria

AU - Battiston, Monica

AU - Spina, Michele

AU - Di Raimondo, Francesco

AU - Pinto, Antonio

AU - Crispo, Anna

AU - Grimaldi, Maria

AU - Franceschi, Silvia

AU - Dal Maso, Luigino

AU - Serraino, Diego

PY - 2016/6/23

Y1 - 2016/6/23

N2 - Background: Hepatitis C virus (HCV) has been consistently associated to non-Hodgkin lymphoma (NHL); conversely, few studies have evaluated a comprehensive serological panel of hepatitis B virus (HBV) in NHL etiology. Methods: We conducted a case-control study in Italy in 1999-2014, enrolling 571 incident, histologically confirmed NHLs and 1004 cancer-free matched controls. Study subjects provided serum for HCV and HBV testing and for HCV RNA. Odds ratios (ORs) and corresponding 95 % confidence intervals (CIs) were estimated by logistic regression, adjusting for potential confounders. Results: Circulating HCV RNA was detected in 63 (11.1 %) NHL cases and 35 (3.5 %) controls (OR = 3.51, 95 % CI: 2.25-5.47). Chronic HBV infection (i.e., positive to HBV surface antigen - HBsAg+) was found in 3.7 % of cases and 1.7 % of controls (OR = 1.95, 95 % CI: 1.00-3.81); a significantly elevated OR was observed for B-cell NHL (2.11, 95 % CI: 1.07-4.15). People with serological evidence of past HCV or HBV infection, vaccination against HBV, or detectable antibodies against HBV core antigen (anti-HBc+) alone were not at increased NHL risk. Conclusions: Our results support a role of chronic HCV infection in NHL in Italy and suggest an involvement of HBV infection. Associations were clearest for B-cell NHL and diffuse large B-cell lymphoma. Prevention and treatment of HCV and HBV infection may diminish NHL incidence, notably in areas with high prevalence of hepatitis viruses infection.

AB - Background: Hepatitis C virus (HCV) has been consistently associated to non-Hodgkin lymphoma (NHL); conversely, few studies have evaluated a comprehensive serological panel of hepatitis B virus (HBV) in NHL etiology. Methods: We conducted a case-control study in Italy in 1999-2014, enrolling 571 incident, histologically confirmed NHLs and 1004 cancer-free matched controls. Study subjects provided serum for HCV and HBV testing and for HCV RNA. Odds ratios (ORs) and corresponding 95 % confidence intervals (CIs) were estimated by logistic regression, adjusting for potential confounders. Results: Circulating HCV RNA was detected in 63 (11.1 %) NHL cases and 35 (3.5 %) controls (OR = 3.51, 95 % CI: 2.25-5.47). Chronic HBV infection (i.e., positive to HBV surface antigen - HBsAg+) was found in 3.7 % of cases and 1.7 % of controls (OR = 1.95, 95 % CI: 1.00-3.81); a significantly elevated OR was observed for B-cell NHL (2.11, 95 % CI: 1.07-4.15). People with serological evidence of past HCV or HBV infection, vaccination against HBV, or detectable antibodies against HBV core antigen (anti-HBc+) alone were not at increased NHL risk. Conclusions: Our results support a role of chronic HCV infection in NHL in Italy and suggest an involvement of HBV infection. Associations were clearest for B-cell NHL and diffuse large B-cell lymphoma. Prevention and treatment of HCV and HBV infection may diminish NHL incidence, notably in areas with high prevalence of hepatitis viruses infection.

KW - Case-control study

KW - Hepatitis B virus

KW - Hepatitis C virus

KW - Non-Hodgkin lymphoma

UR - http://www.scopus.com/inward/record.url?scp=84978245787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978245787&partnerID=8YFLogxK

U2 - 10.1186/s13027-016-0073-x

DO - 10.1186/s13027-016-0073-x

M3 - Article

AN - SCOPUS:84978245787

VL - 11

JO - Infectious Agents and Cancer

JF - Infectious Agents and Cancer

SN - 1750-9378

IS - 1

M1 - 27

ER -